Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GLA | P06280 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904657 | 0.86 | NPC1 (0.42) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7897320 | 0.86 | NPC1 (0.43) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7903324 | 0.83 | NPC1 (0.41) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7904228 | 0.82 | NPC1 (0.39) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7904691 | 0.78 | LMNA (0.47) | GLACYP2D6CYP2C19KMT2A | |
| SCHEMBL7899046 | 0.78 | ALDH1A1 (0.41) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7904142 | 0.78 | CDK1 (0.34) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL612105 | 0.78 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1GAAKDM4EGLA | |
| SCHEMBL7905091 | 0.77 | CHEK1 (0.50) | NPC1SMN1; SMN2ALDH1A1GAAKDM4E | |
| Pbt-434 SCHEMBL30080956 | 0.76 | TLR7 (0.39) | NPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| WO-2010071944-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NDUFV2 | NPC1 859/4885SMN1; SMN2 354/4885ALDH1A1 866/4885 |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | NPC1 1143/4885SMN1; SMN2 525/4885ALDH1A1 937/4885 |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | NPC1 1143/4885SMN1; SMN2 525/4885ALDH1A1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.